Having made some solid capital gains from various ophthalmology and niche med-tech companies in the past, I looked into Synergetics (SURG)
hoping to find an interesting growth opportunity that the Street has
simply not caught on to yet. While I did find a decent company with some
growth and capital appreciation potential, the magnitude of that
potential was maybe not quite what I was hoping to find. Though I intend
to monitor this company in the future to see whether they can
capitalize on any disruptions at Valeant's (VRX) Bausch + Lomb business, I'm not sure I see quite enough opportunity today to merit a strong recommendation.
Continue reading here:
Can Tiny Synergetics See A Big Surge?
No comments:
Post a Comment